Breaking Protocol

Tilda

The clinical trial industry is stuck in an innovation impasse, weighed down by outdated processes, layers of bureaucracy, and a systemic inability to prioritize those on the frontlines - patients, sites, and researchers. Tune in every week as Tilda Research CEO Ram Yalamanchili interviews clinical trial leaders at the cutting edge of innovation who are breaking past the current paradigm.

  1. 11 Jun

    Gaurav Bhatnagar: The AI Reality Check

    In the final episode of Season 2 of Breaking Protocol, Ram Yalamanchili and Gaurav Bhatnagar reflect on the biggest lessons, themes, and insights from a season featuring clinical research leaders, CRO executives, sponsors, and innovators across the industry. The conversation explores a fundamental shift taking place in clinical trials: AI is moving beyond demos and pilots and becoming an operational teammate that executes work, delivers measurable ROI, and changes how organizations think about clinical operations. Ram and Gaurav discuss the difference between AI hype and real-world implementation, the growing importance of AI fluency, the economic pressures driving adoption, and why some organizations are moving dramatically faster than others. Key topics include:• Why AI teammates are becoming embedded in clinical trial operations• The difference between AI potential and proven results• How AI fluency is emerging as a competitive advantage• The changing economics of CROs and clinical operations• Why sponsors are beginning to expect AI-driven efficiency gains• How organizations can accelerate adoption through leadership alignment• Lessons learned from industry leaders including Paulius, Krishna Cheriath, Shobhit, Paula Brown Stafford, and George Magrath• Why operational AI creates immediate feedback loops and measurable outcomesAs Season 2 concludes, Ram and Gaurav share their perspective on where the industry is heading and why the next generation of clinical research organizations will be defined not by software they buy, but by how effectively they integrate AI into the way work gets done.

  2. 25 Mar

    Shobhit Shrotriya: Pharma is Moving from AI Pilots to Production

    In this episode, Ram Yalamanchili sits down with Shobhit Shrotriya, Managing Director of Global Life Sciences R&D Operations at Accenture, to unpack what it will actually take for AI to move beyond mere pilots to full production in clinical research. Drawing on deep AI expertise, as well as decades of experience in clinical operations, Shobhit explains why most organizations are still thinking too narrowly about AI, why pilot fatigue is real, and why point solutions often fail to solve the underlying workflow problem. The conversation explores the full evolution of clinical data operations, from paper-based studies and early EDC adoption to today’s push toward AI-led transformation. Along the way, Ram and Shobhit dig into the harder questions most vendors and sponsors still avoid: fragmented data ecosystems, weak governance, poor process redesign, limited interoperability, and the importance of building systems that can actually scale in regulated environments. They also tackle one of the most important issues in enterprise AI adoption: trust. Shobhit makes the case for responsible AI frameworks, human-in-the-loop decision making, and a more realistic approach to evaluating what “failure” actually means in AI pilots. The result is a practical, executive-level discussion for leaders in pharma, biotech, CROs, and clinical data science who want to understand where AI can create real value and where the industry still has work to do.

  3. 11 Mar

    Krishna Cheriath: AI is Disrupting Clinical Research Already

    Enterprise software has dominated how companies operate for decades. Krishna Cheriath, Head of Clinical Research Data and AI at Thermo Fischer Scientific, believes that model is being broken by AI teammates. In this episode of Breaking Protocol, Krishna joins Ram Yalamanchili to discuss how AI teammates are fundamentally disrupting the enterprise technology stack itself. Instead of navigating layers of applications and workflows, future knowledge workers will interact directly with data through AI agents that reason, plan, and act. Krishna brings a rare perspective at the intersection of technology, AI, and pharmaceutical R&D. As Head of Digital and AI for Clinical Research at Thermo Fisher Scientific and former Chief Data & AI leader at Zoetis and Bristol Myers Squibb, he has spent decades deploying enterprise technology inside some of the world’s largest life sciences organizations. The conversation explores why clinical trials still struggle with timelines and operational complexity, why automation alone has not delivered the expected breakthroughs, and why AI may represent a fundamentally different paradigm. They also discuss the growing importance of AI fluency across the life sciences industry and why both individuals and organizations must rethink how they learn and adapt in an era of AI-augmented work. Topics covered include: • Why clinical trial operations have not improved as much as expected • The limits of automation in drug development workflows • Why AI could disrupt the entire enterprise software model • The concept of a human-AI workspace replacing traditional applications • How AI fluency will shape the future of clinical research leadership For leaders in pharma, biotech, and clinical research, this conversation offers a clear look at how AI may reshape both the technology stack and the way scientific organizations operate.

About

The clinical trial industry is stuck in an innovation impasse, weighed down by outdated processes, layers of bureaucracy, and a systemic inability to prioritize those on the frontlines - patients, sites, and researchers. Tune in every week as Tilda Research CEO Ram Yalamanchili interviews clinical trial leaders at the cutting edge of innovation who are breaking past the current paradigm.